

References

1. Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? *Eur J Cancer*. 2004;40:1825-1836.
2. Ives N, Stowe R, Lorigan P, Wheatley K. Biochemotherapy vs chemotherapy for metastatic melanoma: a meta-analysis of the randomized trials. *J Clin Oncol*. 2007;25(suppl 18S):483s. Abstract 8544.
3. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. *J Clin Oncol*. 1999;17:2105-2116.
4. Ribas A, Antonia S, Sosman J, et al. Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma. Presented at: American Society of Clinical Oncology Annual Meeting; June 1-5, 2007; Chicago, Ill. Abstract 3000.
5. Gomez-Navarro J, Antonia S, Sosman J, et al. Survival of patients (pts) with metastatic melanoma treated with the anti-CTLA4 monoclonal antibody (mAb) CP-675,206 in a phase I/II study. *J Clin Oncol*. 2007;25(suppl 18S):478s. Abstract 8524.
6. Weber JS, Hersh EM, Yellin M, et al. The efficacy and safety of ipilimumab (MDX-010) in patients with unresectable stage III or stage IV malignant melanoma. *J Clin Oncol*. 2007;25(suppl 18S):477s. Abstract 8523.
7. Pashenkov M, Goëss G, Wagner C, et al. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. *J Clin Oncol*. 2006;24:5716-5724.
8. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. *Proc Natl Acad Sci USA*. 2004;101:14639-14645.
9. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. *J Clin Oncol*. 2005;23:2346-2357.
10. Weber J, Targan S, Scotland R, et al. Phase II trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with a multi-peptide vaccine for resected stages IIIC and IV melanoma. *J Clin Oncol*. 2006;24(suppl 18S):102s. Abstract 2510.
11. Wolchok JD, Gallardo H, Perales M, et al. Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. *J Clin Oncol*. 2007;25(suppl 18S):119s. Abstract 3005.
12. Chudnovsky Y, Khavari PA, Adams AE. Melanoma genetics and the development of rational therapeutics. *J Clin Invest*. 2005;115:813-824.
13. Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. *Br J Cancer*. 2006;95:581-586.
14. Agarwala SS, Keilholz U, Hogg D, et al. Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma. *J Clin Oncol*. 2007;25(suppl 18S):474s. Abstract 8510.
15. O'Day S, Gonzalez R, Lawson D, et al, for the 4783 Melanoma Study Group. Subgroup analysis of efficacy and safety analysis of a randomized, double-blinded controlled phase II study of STA-4783 in combination with paclitaxel in patients with metastatic melanoma. *J Clin Oncol*. 2007;25(suppl 18S):479s. Abstract 8528.
16. Perez DG, Suman V, Amatruda T, et al, for the North Central Cancer Treatment Group (NCCTG). Phase II trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma. *J Clin Oncol*. 2007;25(suppl 18S):487s. Abstract 8560.
17. Bedikian AY, Millward M, Pehamberger H, et al, for the Oblimersen Melanoma Study Group. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. *J Clin Oncol*. 2006;24:4738-4745.

Self-Assessment Questions

Select the 1 best answer to each question and circle that letter on the Answer Grid on the Evaluation Form (page 7).

1. Single-agent dacarbazine confers a response rate of approximately:
 - a. 5%.
 - b. 15%.
 - c. 20%.
 - d. 25%.
2. Tremelimumab and ipilimumab target:
 - a. B-Raf.
 - b. CD137.
 - c. CD40.
 - d. CTLA-4.
3. The primary adverse effect associated with anti-CTLA-4 antibodies is:
 - a. Colitis.
 - b. Embolism.
 - c. Hypertension.
 - d. Pruritus.
4. A phase 2 study of a TRL-activating agonist showed a response rate of:
 - a. 10%.
 - b. 15%.
 - c. 20%.
 - d. 25%.
5. In a recent NCI study employing T-cell adoptive transfer therapy, the reported objective response rate was approximately:
 - a. 10%.
 - b. 25%.
 - c. 50%.
 - d. 75%.
6. In melanoma, the most common mutation in the Ras/Raf/MEK/ERK cellular pathway occurs in:
 - a. B-Raf.
 - b. ERK.
 - c. MEK.
 - d. Ras.
7. Sorafenib as a single-agent has shown:
 - a. No activity.
 - b. Limited activity.
 - c. Moderate activity.
 - d. Substantial activity.
8. Elesclomol (formerly STA-4783) is thought to:
 - a. Have significant single-agent activity.
 - b. Induce oxidative stress.
 - c. Inhibit angiogenesis.
 - d. Inhibit cell growth.
9. A single-arm, phase 2 study of bevacizumab by Perez et al in combination therapy resulted in a:
 - a. 15% response rate and 50% stable disease.
 - b. 15% response rate and 60% stable disease.
 - c. 10% response rate and 50% stable disease.
 - d. 10% response rate and 60% stable disease.
10. A subset analysis of a recent phase 3 trial of dacarbazine found the addition of oblimersen was of benefit to:
 - a. All patients.
 - b. No patients.
 - c. Patients with elevated LDH values.
 - d. Patients with normal LDH values.

